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Over 25 years ago, the National Department of Health (NDoH) 
declared the first week of August National Rheumatic Fever Week 
following the efforts of John Barlow, Budgie van der Merwe and 
others to focus the attention of the nation on the need to implement 
proven interventions to reduce the incidence of acute rheumatic fever 
(ARF) and the prevalence of rheumatic heart disease (RHD).[1,2] It 
was at this time that ARF was made a notifiable condition, although 
the uptake of notification was subsequently found to be suboptimal. [3] 
In October 2005, the NDoH hosted the 1st Pan-African Workshop 
on Acute Rheumatic Fever and Rheumatic Heart Disease, together 
with the World Health Organization (Africa Region), the World 
Heart Federation, the Pan-African Society of Cardiology and the 
South African Heart and Stroke Foundation, where the Drakensberg 
Declaration was adopted.[4] The Drakensberg conference issued a 
clarion call to African governments and their ministries of health to 
initiate national programmes to eliminate ARF and control RHD by 
raising awareness among the public and professionals, measurement 
of the burden of disease through surveillance studies, improvement of 
medical and surgical care through advocacy, and the widespread use of 
penicillin in primary and secondary prevention activities (the A.S.A.P. 
Programme).[5]
A.S.A.P. has inspired new research that has provided vital infor-
mation on the status of ARF and RHD in Africa and the world. [6] 
South African (SA) studies reveal a changing pattern of disease at 
hospi tal and population levels. Hospital-based studies show a high 
incidence of congestive heart failure caused by RHD (average of 
25 cases/100 000/year in Soweto) that is associated with high 60-day 
and 180-day mortality rates of 24.8% (95% confidence interval (CI) 
13.6 - 42.5) and 35.4% (95% CI 21.6 - 54.4), respectively.[7,8] This high 
burden of heart failure and mortality in adults has to be contrasted 
with a falling caseload of ARF and RHD in children, as demonstrated 
in Soweto recently (Fig. 1). Furthermore, there has been a fall in cause-
specific mortality from RHD over the past 15 years (Fig. 2). These 
changes are consistent with a transition of ARF/RHD from a condition 
of childhood to a mature endemic disease of adults. The changes 
may reflect a ‘Mandela dividend’ associated with the improvement in 
access to primary healthcare and rising socioeconomic status of South 
Africans since the advent of the new SA in 1994.[9]
The ‘In Practice’ article in this issue of SAMJ on the role of 
screening echocardiography for RHD in the school health pro-
gramme by Shung- King et al.[10] and the letter describing a regimen 
for the painless administration of intramuscular penicillin by 
Madeira et al.[11] address important issues in the quest to end 
RHD. The commentary by Shung-King et al.[10] is a response to 
an echocardiographic screening study of schoolchildren in Cape 
Town that showed a prevalence of latent RHD of 20 - 30 per 1 000 
among asymptomatic schoolchildren, although about 50% of these 
cases revert to normal after 5 years of follow-up.[12,13] Screening 
echocardiography is not recommended as a routine test in the school 
health programme until studies of its impact on prognosis and cost-
effectiveness are conducted.10,14] The advice by Madeira et al.[11] on 
the use of lignocaine as a diluent for benzathine penicillin is relevant 
not only to practitioners who use injectable penicillin on a regular 
basis for the primary and secondary prevention of ARF, but also to 
those whose patients need penicillin prophylaxis against recurrent 
infections in sickle cell disease and immune deficiencies.[15,16]
There has been significant progress in the uptake of the A.S.A.P. 
call by African governments. In June 2015, the heads of state of 
African countries endorsed the Addis Ababa Communiqué, which 
sets out seven actions for addressing the barriers to RHD control 
that were identified in the REMEDY study.[17,18] These are as follows: 
(i) creation of prospective disease registers at sentinel sites in affected 
countries to measure disease burden and track progress towards the 
reduction of mortality by 25% by the year 2025, as mandated by the 
World Health Organization;[19] (ii)  provision of an adequate supply 
of high-quality benzathine penicillin for primary and secondary 
prevention; (iii)  improvement of access to reproductive health servi-
ces for women with RHD and other non-communicable diseases 
(NCDs); (iv)  decentrali sation of technical expertise and technology 
for diagnosing and managing ARF and RHD (including ultrasound 
of the heart); (v) establishment of national and regional centres of 
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Fig. 1. Number of cases of ARF and RHD presenting to the Paediatric 
Cardiology Unit at Chris Hani Baragwanath Hospital, Johannesburg, 1993 - 
2010.
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Fig. 2. Cause-specific mortality rate due to RHD in the SA population, 1997 - 
2012. (Dotted lines = the confidence intervals of the estimates of mortality.)
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excellence for essential cardiac surgery for the treatment of affected 
patients and the training of cardiovascular practitioners of the future; 
(vi) initiation of national multisectoral RHD programmes within 
NCD control programmes of affected countries; and (vii) fostering 
of international partnerships with multinational organisations for 
resource mobilisation, monitoring and evaluation of the programme to 
end RHD in Africa.[18]
SA has the conditions that are required for success in eradicating 
ARF and ending RHD. The NDoH has prioritised the prevention 
of the disease through initiatives such as National Rheumatic Fever 
Week, the inclusion of ARF among notifiable conditions, and efforts 
to improve access to primary healthcare. Health practitioners need to 
play their role by notifying cases of ARF, treating all children with a sore 
throat with penicillin according to the SA guidelines,[20] and entering 
all our patients with RHD in the electronic 
register.[21] These measures, together with 
other actions outlined in the Addis Ababa 
Communiqué, if imple mented across the 
health system, will hasten the demise of 
ARF and bring RHD under control by the 
year 2025.
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